:

      

    

 ! " #

    
The Impact of Direct-to-Customer Advertising (DTCA) on
Customers Decision Making: A study on Hashemite
Kingdom of Jordan Customers

: $

%& ' 

 

: (

& )' # 

*" ) $ +,& - -  *,' . 0/ #  123 . 

*" ) $ 

*" #

" 4 5-

‫ب‬
‫ج‬
‫د‬

‫
‬

‫‪.!'
 $ 7!- #   .'  ………… $‬‬

‫‪.'
 $ 7!#
5 9  *5-  ………… $‬‬

‫‪.),
- $ 7


!:
! !  ………… $‬‬

‫‪3;< ; = -  23 >?  9 - 9 3 5- $‬‬

‫ ) ‪.3 -‬‬


  #

$ ! "#   !

  
     
.+ , $ %  $#&'( $ ) *  $ *

./ ' ",  * +#   . ,       
,",  (/ 0 %( 12 , 0  1 3&'(
 4 

."44# %  $ 6 

, 7 " 0 8  "&
9  :      

." 0 ", +  " )  

 ; <#
 (  *=

>#

;*  0
‫و‬

(Contents) .' * -

'I, H?

% JI

K ! !-  

L 3

1   #

 .' 

M * - 

* 4' 

 5 N +&

O -! N +&

1 :   5 9P!  : *" *,I

2  

3    #

4      .?

5    ( 3

6    3

7  - .',

8     '

8    . '
‫ز‬

9    K2!

10    5  :
! *,I

11  

11  " 4

12
! "  " 4

13 ['
! "
!0 , 4 

14 '  %5 5!,

14 %5 5!,

15 

16   

16 H 

16 H 
 

17
!0 , 4 . '

18  " \  (#

19   

19    (5

19     12!

21   

! 

22  " L   L -

23     <

‫ح‬

26 L    L 2N ) $ %'   .! ] (#

27   4 H !

30 .! > #

31  .  

36 . L -   : ^ *,I

37  

37    -!

37    >-

37    !

39 .5  *,'  ,    .  

41 ,' %"

42     )  4 ,

44 .?I &  *' \! : >  +I

45  

45      -

52    .? &

61 .,  \! ! : O& *,I

62  
‫ط‬

62 \!

64 .,

66 >-  

66 !# >- 

67 !-" >- 

72 !0 : 1 4'

79 #' L<  :2 4'

‫ي‬

* - 

'I, H? * -  / *,I 

39 "#' " , "  1( ,D (1A3)

40 ", "( "G H&'* (2A3)

43 ", 0 * , 04K4  (3A3)

44 ",  2 1K ) (4A3)

47 " " 1#(D ",# 1,  (1A4)

0#' 0  12   L ,

49 1 " 1#(D ",# 1,  (2A4)

1  ", "(  1 ,D ;  
"#' 1 '

50 ;  " 1#(D ",# 1,  (3A4)

1  ", "(  1 ,D "
"' )D 

52 1 ,D " 1#(D ",# 1,  (4A4)

 ) 1  ", "( /

54 0#' 0  4 4   #( # O& ( (5A4)

P ( "% "( "  0

 ) 

 
K  

55 )  0#' 0  4R  (1) ) (β) ) (6A4)

K  
P ( "% "( "  0


 
‫ك‬

56 +* 0  4   #( # O& ( (7A4)


K  
P (
 ) 


."% "( "  0



57 &2 0  4   #(D # O& ( (8A4)


K  
P (
 )  +

"% "( "  0



58 1K*  0  4   #(D # O& ( (9A4)


K  
P (
 )  "&

"% "( "  0



59 T  0  4   #(D # O& ( (10A4)


K  
P (
 )  "(

"% "( "  0



61 " 1 ' 4 #(D # O& ( (11A4)

 
K  
P (
 ) 

"% "( "  0

62 
 .' )D ;( #(D # O& ( (12A4)

0
 
K  
P (
 )

"% "( " 

‫ل‬

*#" 

['I, H? *#  /*,I 

9 ", U( (1A1)

16 (Marketing ",  ! (1A2)

Goals)

21 c( 

G +

() (2A2)

'  
K 

22 0(D'
K  7,  (3A2)

27 + 1(K  4d ! (4A2)

0#' 0  : 

28
 + 1(K  12(' (5A2)


G +/
1'
‫م‬

4' 

['I, H? 4' /*,I 

72 ", + 1

79
 #
,R "&) 2
‫ن‬

5 N +&

0 "& % ) 
&  0(D' 7,  4
!  ", 1

."% "( " 

0 f) R 0#' 0  64 e(


 !  "4  ", ! 7# 

1)  ($& 1K*  0  "( 14R  0  ,* 0 ,&2

L ,f 4  .' )D  " 1 ' 4 e(


/ ,


1 : e + (32) 1 "( , '  ,

 "& 1 *

* f, 1f92 f * 1( :  e
9 0 ,", "(
 $

f i (484)
 ", "( 1(  ,SPSS "  D  "&'# "#

."% "( "  0

&

#  "
/  ", ! 7#  "&'# ;,

  * ,  

:%
 O& (
  / ", 1' % 9 ", 1(

f) f 0#' 0 )  "&'#/ "D  4  ", O& (  1( 

4  ."  (

 
K  
( "% "( "  0


+f f&2 0#' 0 
 +* 0#' 0   "&'#/ "D 

0   "&'#/ "D  4  

  ."( T D 0#' 0 


  ,
 )  " 1 '  $& 1K*  0#'

.
 )  . L ,  "&'#/ "D  4 
‫س‬

ABSTRACT
The study aimed at revealing the Impact of Direct-to-customer

Advertising on customer decision making in Hashemite Kingdom of

Jordan market.

In order to achieve the objectives of the study, the researcher designed a

questionnaire consisting of (32) paragraphs to gather the primary

information from study sample. The Statistical Package for Social

Sciences (SPSS) program was used to analyze and examine the

hypotheses. The study sample consists of (484) individuals from the

customers.

There is significant statistical impact of Healthcare awareness on

customer Decision making .and there is significant statistical impact of

perceived severity and perceived benefits and perceived side-effect on

customer Decision making.

There is no significant statistical impact of Drug-Drug interaction and

source of Healthcare information and economic factor on customer

Decision making.
1

*" *,I

   5 

  •

   # •

    .? •

   ( 3 •

   3 •

 - .', •

    ' •

   . ' •

   K2! •
2

:  •

TfD UKf  ( , 0% k" " 1 ( 

 +# " 

"  0 14# 1G 

 4  .(Lipincott,2010) *l %9 9 %(

f  "f  "f 1f(  k"f

f
Kf  7,f  0f "9

+f#  D 1( " 


 p   k
 )

 7, 

f "f2  f

Rf k; T 1* %(  k" 7,  7 9


Tf )
 ")K* p 
R( 0    
 + ;,


 " 1 
 % e  p    k(IIZUKA,2005)


.
, #

>f# " " 1  1 09


   1) 1((4 " 0

f
&f f
Kf  Kf*
 
  " 7,  " ",

."' +, 1#  ; +



:f f / kMerck" f )

 7  # (DTCA)
& 
K  

%(#  k1981  0 Reader's Digest " 0 %c . k.& ;% D y

+/ 1 ,1997  0 ,7,  7, 0 0 1   T $

"f% ~f R 1* 

K } D  " D ) "p

1 f : c(   k1, :

 # k7,   c(   '#

.1 8  %   0 . * / "

3

  , 7 "(


k" 7, 0 0 G  
 p  

&, *
 D/ k
K 
 €(  4 4 R# 1  ''*
 

K%, O 
 €(  4 *  1( ( * 1&92 "2 *  K 

.   $ 7, "'* 0( 7,/

:   # •

02 ,   $    ,+ " ' 1) 0 0(D' 7,  

 D  "* $& " ,  1G  7,D 0 + $,( y 2(D c

"#  R/ '   "   0(D' 7,   + 1  , R

.
&
 "( 

7f D
# T 0 ,1 # T
 G  "( 0
 " 
 D/

0f * 
9 " 7,D 0 %#(  D/ 1  ,D T 7,

.e /  *

f f #
 0
 
K  c(    ", "  4 

 "   &2 1(K  

 4 ")K " 
K9 " +'

.
&
4

:    .? •

0f
f )  0#' 0  "&'#/ "D .4  D : H01 •

: €2 $( (α 0.05) L , ( "% "( " 

) 
 +* 0  "&'#/ "D .4  D :H01A .1

(α 0.05) L , ( "% "( "  0



)  + &2 0  "&'#/ "D .4  D:H01B .2

(α 0.05) L , ( "% "( "  0



f "& 1K*  0  "&'#/ "D .4  D:H01C .3

(α 0.05) L , ( "% "( "  0

 )

f "( T  0  "&'#/ "D .4  D:H01D .4

(α 0.05) L , ( "% "( "  0

 )

f) f "f 1 ' "&'#/ "D .4  D :H02 •

(α 0.05) L , ( "% "( "  0



0f ) 
 .')D ;( "&'#/ "D .4 D :H03 •

(α 0.05) L , ( "% "( " 

5

+4/ K*
 39 +' ", "  %c/
 ,    ( ,

:1Dd, 
 

"f  0f
& )  R%#' $   4R L  :D •

„"% "(

"f  0f
& )  " 1 ' 4R L  :(4 •

„"% "(

"f  0f 0& ) 

 * L ,4R e(  :44 •

„"% "(

   ( 3 •

Kf  f
(
& 1)  4R  0 " 1 4  !  .1

.% 

"  0
& 1)  4d   " 1 ' 4  !  .2

."% "(

"  0 "… (K  K*

(& 1)  . L ,4 " .3

."% "(

"f( "f  0f (" 1 )  €(' +2 1/ 1'  .4

.
& 1)   0(D'
K  4R # "%
6

:   3 •

:"  ;(
 %  ",  ;,

$(//
& 
K  8 0  &K 1,
 %(   "  .1

f (D 1f2    %, , ", 

   0 " 1,  D

. 7,  "  ,

:(f' 0   # 

K  "  ,
&
= "  ",   .2

."#  7# 

f% "f O& (

&
= 
(  :(' "2( ", 
 :)  .3

."% "( "  0 0(D'

K  7,  0) 0  ,,  ",
7

: - .', •

&f "f2 *
K  7 "  "… O   :  

(Costea, 2009).0 :  $( 4 "

 Hf
f f *K 1

 "  *   + 0 : .  

(John, 2011) ."  :  

$ 2 $  (  e, .  , 9# 0 ;) " :

',


(WHO, 2010).0#' :9  4R

Mosby's, ) .
f f* +* "   O& ( 2 ' : L   )&


(2009

L , 
 * "   :( # "#' " :1-  I



(WHO, 2010). 0'*

ef
"2 * " "  ", " ,  " :-5 .& 


(Lippincott, 2007).#
 * ") 

c( TG ,"p 4l / "9/ ",# 4=   :!- J "


(Aronson, 2000) .+9  +2 1( / 

8

f "f "#'   "R#

"d, "c( 0:(FDA)L    L 2N ) $

"f)K $f     ," "p "K,

  R  c(  ! K*

(FDA,2011).("' 1  +#  1  ! )

,(D "#'

f(

&f + € 0  " 0 :(OTCeDrugs) I,    "

(FDA, 2011)."(() ) .
… *

:     ' •

:0  " " "( "(  ", # 1(

."% "( "  :   !#  '

2012A2011 0,  :!  '

."% "( "  0 " 7,

&
 "( 4 :  '

"'* 0( 7, " " 7,  " 1, ( :5  '

. 0(D'
K   0

:   . ' •

:0  %9
 +# O& (  1 6# 6)( ",  0   0 

.
(
&
 "(  '  >#  •

. 0  0 ># "  1(   ( •

9

:   K2! (1e1)

(1A1)  
10

! *,I

 .    9P! 

  •

 " 4  12! •

 •

i " \  (# •

   •

 .   •
11

:[ 

j!    *-

' .#  .   *,I 23 j!

. P! 3 )<! k ?  4  H! 2  ^'

12; 5"  . N ) 9P! 

%l ^ '  ? *,I 23


12; &m  *# ) I .!#

  , . 2  .   *&  (   

.  

: " 4

1f( 2010  02 ,1& ;,  0 1 ('  

 " " (' 

f#( :f 0f D f 61.5 f#

,( (=
,( "  3

;,f ,(Pharmaceuticals & Biotech Industry Global Report 2011),

7f, f +f G9 19i  "9 " 1(, 0 &% *9  

82( 0 "(' 1  1* 0 0  + 1G  "(D'


 0  . 0& ;( 0 "# *

l

& 1)

. (Saxena, 2006) .7, 


12

:
! "  " 4

 f ef :f , "f Uf ( ,f( .) L ,

 L 9# 1) 0

.1f f f  f D 7f, f/ $f L f ,O f(  c '

7,ff >ff#  ff  Hff* €ff "ff #

ff ff ff  

1 ,f "f( 0f "f "f, $

 ."#' "R    0(

f)
f, f# f "f'* "f 12f , "f 1f*
 "

.(Arab health word, 2008)+* 1(, 0   :,  

D
ff 249 ; ff% ) ff "ff
 1 ff, k2005 ff 0ff

7,ff 0ff e% ,ff

ff .ff
ff ’80
ff ff4  .k0ff 

f k2005 f 0f

f f 0 # D ,, 1(  .0(

f 286.8 +f#  1f 1f' 1fG .7,f

f ’75k4 f4 

."(' !'( "  + "R / k2005  0 D

'f  ( 2011A2008)
f ;,f# .(,   %10 0( 7, 0 (
 

'
 ,2012  # D
 540  d(  ;,# 0( 7, 1

.f ,f(   0( , ( $,  (  .2007  0 D
 336

Pharmaceuticals&Biotech )7, 0 *9   4 ) . % 2.8 ",( L 

(Industry Global Report ” 2011

13

updated Business Environment )"f4# f  ;f  "f#&K ",f( 

:f 0f
4  
 D ( 8,  ( 1' k (Rankings,2012

f 
 ' "9 7, 02 ( 2
 0    .7,

"( *  #D " " ( *  / L  7, . c(  " 

7, T%( ") 4  4 $   0# 1) 0 ."7,

( c( 

"f(" 7f, 0 4 ) 1) 0  + "  (

 # K*


.+* + 2

) $ %;'2010 5 <!

!0 ,
 4 *'  •

:(JFDA,2011) ! " L    L 2N

",f(  ,"'  +% # H* 10,000 6D 6'9151 e(

6& 6  , 273  , 0# :  "' 1920 e

= 
  1'

.1'  .G

500 0f(
f
G +/ ;,# 2010  –  0  7, # ",(

0f %26 eK% f, ,D

 370   .R%(%74 '  .D


,(",f(
 6.2) D 80 : # 2 $ eK% , 
  .0# 7,

fG +/ ;,# %20 – 15 : " eK% , "(, +

   $  

.9

14

:   %5 5!,

D ;f
('f
 /D 1 10  " 1 0 7, #
 p

;f f "f 7f, 0f f( f# 1 #D

 %40 ;  D
G

(JFDA,2011).%18

250 %,f +f e  0( 7, 0 "  " "  280     

.6  , 6 '*

f2  8(
 ; "2'
 0 " ," 7, 0 1G   c 0

,% "# " "' 3&

 "2' 0  "…  c( "2' 0 " 

f)}
& 82(   "4
  "2' U # D 0 " : ; $( 

UK .  ;(

 U* ; $( . UK "2   %( +4 y
˜ ( %

(Syndigate, 2009) .+ ;( 2 

15

: •

( 1(  19  3000 ( " 1(K   ,

(, !D= (
K  %c

f f Tf .f 7 f ;f 1( 1™ 

K }
'

( Hall,2007)
%

f f !f #  "  ") 1

), * , 0# 1) 0

f f* 0f 0,  O # 7

(Borden, 1994)%#  7,

!f 7f#  "f2 * 7f, 0  1  %* , ",  1

,Product O f
ff(),(4Ps) ; McCarthy f
ff, f
ff) (McCarthy, 1999)

f
f
    .(Place :  1() promotion O ,Price‫ا‬

f 6#
K   O  " 4  *D 0 7,  ! y( 

."  0 ># *  #D $#  , 7  

16

,", ,",,d # 0'* p '  "  " .R%( 

K  !


 0 6 ,, 6'(

K  3' .(Boone, 2012)  .
 +  . "*

"'* "R "( 

  ) 1  1''* 0  ,1 

:(Agnieszka ska, 0  #(  %9 "R  :(

  e(
 . %

1997)

1* :, 1 + •

& ) 1) 1* :, %c/ •

  %c •

+  :, 1 (  •

.O (  "  "K (businessAvalue) + •

1( 0  "2 * K  &,  1(K }    (K ;, + e(

 ,e

1,f  €( + e(

 :( e 
( .%( 
   4 1

:># *  €(   (  

K }

:H 

f& f
Kf  0 4  ," "R  ", "  K  &, 1(

, Attea)(Flyers)1 (Brochures) 1( 1%c  # 1 ) 1K

(2008
17

: * 

.1( (  2  %( ,) +  . #  " ",  >
K 

"f2 f   .% %c  ( " 1 2   "R 

    

f 0 R 2  "
 # " ,
K } "( +  2  
K 

.  0 R 0(4  0 .9 %9 : +' 1' U(
  (

f# 1( ( * 9# 1) 0 ,2 

 0  $ 2 
( G' $92

0#f(  f $f* 0f,) 1f) f&% f (D $f :f,


K 

( .Parkinson,2006).+#

:
!0 , 4 . '

Kf €f( !% ,D 1  , ( + 1#( 1 

 

# 0

0f y + H 1# 7*
K  … "4# 1 D

,
2 *

 D/ .(Saurabh Kumar Saxena, 2010),0f UK "& 1 (' 

"2'
, 0 UK , "

#
   0('
 "   " 

Megha (
f +
K 
 
 / ;  " " 
 "

, 2002).Sinha

f )  "(, y

 %20A15 ) +
9
K 
 ,  

1f) 0f "f 1#f' 0f  "  , 1

(  ,
 4 

(, 2011).Kartik Jain0#
18

i " \  (#

,!('f 
f,, e(% $2(' !K * p
! * ", "
  
/

"f… 0(4 !('  "2'

 " K*
 0  ;     

/
 + 7, "2'
 0  " . " "2' %2' ; 0 

€f( T ",,#"R ,
 7

(# 1'  1(K  7

0f2 ,f
(f) : 
( "  ,   ,e /  1( ,

0f f  "2' "R ",,# 19 €( T !(' K4 +#  1

.(2004 ,Buckley)" "2' U # D %(  ",,# " : !(' 




( 1' D/ %  D 0  " 0% , "2' 0  "… ",( 

: "2' › 

 , % ,
  ,; "2'

:"
 " ",& "
 ! (Corstjens,1991)( , )

f ,
(f
 !' 7# $ . H*  :
 !' A1

."' ,
(,
 ,


.1  2 ,  "' :4d A2

.T : e% , A3

;f
f 6f44 6f
 
 .

 " 
 :
 A4

.($,2( T
 

)T

0
 p
 1  L  0# 1) 0 7,  "( "p !% , 

7,f f "(,f 12( 1)

 2002  02 ," : + ",
19

1f 0f  !'  1( ># D  19 ;  ;#'"

( Canadian Medical Association) Journal."  +# 

+f "2'
 0  " 7,  # D ) ( ,0 # D '  

D  !'( " … –( "  Clarityn
 1 + L  ,


( Buckley, 2004).0 D  1.9 1
  '

   1(K 
 ,+
 % , %,
 " c 0# 1) 0

"f Tf f

 f    .p
 4  "2'
 0  "

(Ehrlich, f  f p

  "% , 1&2 %,   +( T…

. 2010)

:   

0"

K  $  %c 09
 * 0 4# %c 3' 

"(() 1#' ,"2 * 7,  &, 7

& " "… " "

Bryan (,. "f D +f#  1f , 0f f# D  , (K( 0

:,f f( "f 0(D'f 7,  1  , 4 

  2011)A.Liang

(Wosinska, 2004). …

:    )2!

 02 ,+2 / $ + " ( 1K( '(

 0 0(D' 7,  $

 % ,
 D , " " 
( % €

… 7,  

20

f
Kf  0f f 2  
 :) 0 ,0  

* ,


:f(
  , 8( 0  , H* :
R *
 9 1#
(&

0f ;f 3'f 7,f  19 0  " 

G ",,d

  

.(Palumbo & Mullins, 2002 " 1K

1#f' f + +c 8

 
K 
 D/ 7,  p  


 1((4 " 02 .(Wilkes MS. 2000)

 0 %c $ ,

&f, !#'f 1Kf 0

& 
K " 1  1, 09

"  ,    0   #


 % ,
 "#  
  !% K 

(Kessler, 2007)+

1) ,># 1, %   + "  , T ,
 ') 1) 

$f 0f  Rf "c( T :9 "'2 "# / " 
G
 +/


K } 0&  (D 
9   ,
… 2, " 9 R

% 3' "), " 1 

 ,
  % ,  1  R
9 "…

.( Lyles, 2002)"(% 1)K*

c( TG "(K / + .R
 ž #

, f
K  # € ,D 1, >#
 
 ",, 1997  0

Kf  &f,  

K   #  %  

G +/ 1'

0f&
Kf  f "f ( $ ( 1(  
K   0 G   >#

.€,
21

:(Richard, 2005)  p

!  •

."  #  1 0 "  !#' 1K%(


  A1981

f
Kf  f# %d,
   " 

G +/ 1 A1982

.
&

,f* f  


K  "( 

G +/ 1#' A1985

. "  1(K 

K  1#

.D
 12 
K   1' 1' A1989

3'f K  &,  

K   ;

G +/ 1#  A1997

.   (

f  ,f# "(,  0

 + $(K /  "2'
 100
 4  A2001

.+* "( $ 2 9 " (

K 
 %9 ;#,

)/  ";% K 9
"Celebrex
 Pfizer " 

K / ;#,  A2005

.
K   0 9 

G +/

:'  0(D'
K  c( 

G +/
() 4 (2A2)  
22

:f,   ,
 
K 
   0  O& ( G  % " ( 

'f# "9D ,

K   "*9 – 72( 1  1#' 7,

"f 1
     ,( Ram Bala, 2010)   "), "'# 

(Ventola , 2000 f 0  2.5 / 1996  D

 800
 12 

.2011).

:0(D' 7, 

K   

Drug companies

Sales Rep.
DTCA

Consumers Doctors

(Burande.2008)0(D'
K  7,  "
(3A2)  

& /
 ' 0  %  7, 

K    7,   39

.
& + 
 7

,
23

:     <

 
K }
9 $   T T
  0 ># !%

:6  %  "&,  

„% , 4d D

& 62'( D
6 
 "
K /    •

( , 
K   # "' "c(
() 19

G +


 #  , 1
/ 1K 2   :(   ;
 +

K /

. "  1(K }   '2  

K  * 0 "( 4l  

(FDA, 2009)

„* + 1(K    •

:9 (  ,  
 * # 1 (D

G +/ e

1(, 0 $  *  '  # ,R D

6  %& ( 8 1( %(()

%  * , 1 :9

G +/ 8  , "9

"2   

  "&G 1 (  , 0  e
&

(Woloshin, & Welch, 2007).$ *


„
 % # D " * ;,  1(K   •

 8, 7 , # +% p T  + 1(K   

 
/ TD  4 UK T
  , ;' (D +)  
24

(
 + T 0  " *= ( ,#   %( 0((

& !* " ( ,T


(
 H*K # " (
,# 

. # *
 ;'
 * 1(K  "   "
 9

(Business Horizons, 2010 ) ."  "9 "#  €




„
 , :  1(K  .d  •

 !' +
  €9  
K }
9 4

(Kaiser Family , + .d, 

K } " (


  1 ) , T

  ># 
 ,Foundation, 2008).

  %( 92  3' 1 

 ",(  * " ( c#

(Gibbons et al., 2007)..

02 . 4  6 K 4 

 % , 
& 
K (R(1999)
  

"f 7,f 9f f%2

& 
K  K*

 % ,(   $

kCalfee(2002)f)
  c( "% 9 $ . % "#  "K 1*

¬"& 1  :D 4  1)K 0 *(



 % ,
   .

K  " ( % "'* "#' "R  0
  #'

 k"#' "R  

kfc( K*
 " #,
 % ,
 Mintzes (2002)1.
& 

Kf*
f f 0f  "f f 'f# 1 :
 / ;

1f "f    '#  + 9

 %4# 1%c.1(K 
25

k"f…  * 0
 4R

 9 %4# 1%c. " 12'  '#

."2 * " % !' e D 

 f* H*f 
 f

 ; . $( 9(1999) p 

"f f%  "f,

K( . " ",((& )
 " 12' ;

1f 0f
 % ,
 15.100.000
 /  0 1998  0 "R)

 :  2

  k % (K / 
  '# %&
  +# 

 12.100.000/     k

# ;p 0 %80 "(, 0   1

Kf  "f f "

  ."R  ", d(/  0  " 12'

0f "f !fc
f 1 / 1

 "# 
 % , 

"f(k1998 

  ",  % 0 %263/ 12  "(K  1K#

.
 / 1  0 % 2 ",(  €2  :

Kf 
f "f)K / 1) 0  Lexchin and Mintzes (2002) ", 0

4d
& 
K 
 ", 1 ,T2 0  1,
& 

1f  f) .  & 1, %( %(#  . 12'
 ( 0

 " 12' "*   ( 4 ,  1999  1 ",

;, 1999 0 1 >#

 "(4 "  0 3' .9% % e

.
& 
K 

f% ;   e " "2' 

 e&
’92
 1   (


&f fc f f). 09% % 0   + , " "2' .
26

Hf* 1K
 .  *D $R# .
 " 0  *"
 e

f
Kf 
 f f 
R
D Mintzes . Lexchin. "2 )

1Df# Tf 0f e% , ;#, " 7* k
 !' (  14R(&

.% )R  p 1K

iL    L 2N ) $ %'   .! ] (#

 1* !)2002 1999 


G +/ €K , 

$  1'* .

&  7, 
K }
D (
&) 9


K 
 ",  1%c ).2003 R( 0 €K ,D  O& (

 $,  1 4 ,  . e,
 "( €(  4d e% ,

"( $ %K ; $2'


R,
D 
 9

(2004) 8    %  ."(

 %88
 
K   ;,

/ ( "( T

  !  0 1, ; 1 
 e

8(
 
 0(

  , ;,( UK
d, : ;(

* T 
 $ ( 4  # "#'
    #
,

. , 0 $2  " 1K* 

27

0#' 0  : 0 1(K   , ! (4A2)  

&(

:(  0% ,

& 0#' 0 
  1(K  $  7,   4

,9f%90 ",f( "( 4l * 0    %90 ",(   9

1,f2 , f  ,

 * , % 3, D

&
 %86 %( 2 ,

f 1   " * , $  ,%74 ",( %& d, % 3,
&

.0   %12  %35 ;,( 2 * ,D

: 1 .! H !

 f ;,# 12(' 3 /

K 

G +/ 1,) 1995  0

 ,  . #  ,(Reminder advertisements) "  1(K / (1) . (5A2)

(HelpAseeking advertisements) (2) ."f  "K   "' 0 , 

"f 2  UKf " +

 T # 1  . # 1(K / 0
28

f $c(    €(  (ProductAclaim advertisements) (3) , * ,D

+f &2
 *


 D $     
G
 + )

.*

29

:
# (Shaw,2008) 3 

:(Product-claim advertisements)" 1 ( 1(K /

1(   ,$* ,
 ,  + 0 "4K4 €(

 6  4  0


  R(  "   :( * $ 
 "K, 69R(K  0

"R%( 0 "(4 + H* 0 *  :9 ,:( *


 

 02     0( !  ) :9 : ;( / 6( %  R 
K 

.6#D %c ) .R  .  


d,

:(Reminder advertisements) "   1(K 

 ( #   "( / : 
 ,  # 0
K   


1 .  . # D $(  ,
   T  $2  1

*
y'
 2  ,$ K,
 " * ,D " 4

. .

d, 0'  ; $ 
&
 $


:(Help-seeking advertisements)1(K 

4# + ,

T
"  
K / .(diseaseAawareness Advertising) 69 !

TG ,% "   T

+
d,
K  
 ,D  

T 
0  7* " "#  T #
 % , !4  €( 

30

$ "#  1K


 8(  %(    + T

1   6 8


 ", 
K 
 €(  0  

.*

: .! > [#

* , €( 4  1(K  % 1  £* * ,D 0 " 



* !'    . €( . , productAclaim ads 0 £*  

 "(' 1  T   ,"(  +'
 R(

  :(

4  #
 ; 0  1c(  0 R ( , * !' 1 T 

,   . " reminder""

K } 1   4 $  .
K 
 €( 

 €' T T    . "helpAseeking" €( %  


; / $ 


 ;  ,  €2  T   #  G9 €2 

.T   7 ;,(
 $  ,D

31

:  .  

“The Past, Present, and Future of

f( Perri, et al. (1999) "f,

/ ",  1 , Direct-to-Consumer Prescription Drug Advertising”

f ;f  0  4l 4 ,
& 
K   0 "% R9 T*

0f " , ,  7,  + "  ( ,
 ;
 ")K

f "f)K 04 

># O& ( 1( . ",(  7,  c

"f)( "f ( %(,f# 

 ; ")K
  1(K  
/ / ;

€f
  D " , T2*  4R 
9 O& ( 14#  ,


. :2  !, ,
  e(=

"Patient Autonomy and the

f( Zachary & Ginsburg, 2001 "f,


9 , ",  Regulation of Direct-to-Consumer Advertising"

Kf } &f, 7f

 7 ,

G + "c( 
( 

7,f 
 "f, f O& ( 1%c ,
&  4  7,  ",

 ; 
& : 
& L 0#' 0  +   4 $ 

   , %( 0   # ( 3#' *

 ;    ,  1

32

f* + &2

 "(  " 1  1(K  

 

.UK

"A 3-Stage Model for Assessing the

( Vogel et al, (2002) ",

Probable Economic Effects of Direct-to-Consumer Advertising of

7

K  1' )
!  ", 1Pharmaceuticals”

$( O& ( 1(  .) ># 0 " ) + "' )D ) "(

,D
 17;   
K   1' €
 1985  0

 ># ;,( ,D  2.5 / 1' 1'  2000  0 

& + , , " * , 0
,#
 
K    +  +

,D T2* "( / 1 +   K9 " "R  "d, # 

.1) 82( 0

“Direct to consumer advertising in

f( Brekke and Kuhn "f,

"…  7,  4 ", / 1 ", pharmaceutical markets”

>f#
f , :('f 1   4R  ''* , "2' 0  " 7, 

"f%
 ; 1   9 ",     ,
 % , :  2  y

1f(  , "… , c(  D

 *  , L* "%

 1% 

"f%
f
 %# + "%
 1  + &  ",  O& (
33

"# 0 %/ €  
 

 0, 4
 , ,…   c( 

.

 + $  T

“Direct-to-consumer advertising
( Shah, et al. (2005) entitled ",

0f f f  ",  !% and the patient-physician relationship”

Kf  ;,f ;

 ")K 4R
 %K*

 0  "2  %c

 " + # "( R

9 H*R˜
  1(R , :  / ,

 7, 
 O& ( 1(  , + 0
  "*9 14 "( ,% 19

f + 1 ;


 >#
 ;
 ")K
,# / .d

( 0#' 0   04R 8 (  %( ")K

,# / .d  ;

. 09/  
&

“The association of consumer cost-

f( Hansen, et al. (2005) ",

sharing and direct-to-consumer advertising with prescription drug

,"2f' 0  $ ,  "  ,
  ! D !% ",  uses”

"  f,D 4R  O& ( 1(  ,

&  7,   4R e( 

1f( / "f'*

&  7,   " "2' 0  "  , 

!  , €(    %( ")K 1(  ,

G +/

() !/ 1#
34

 ,
 , 7, 
 0 L , 1 7, 0 / (costAsharing)

.T2*( L , .  7,  1 7, "( 4  $10 ; T2*( )

" Direct-to-consumer advertising via

( Swek S. et al, (2005) ",

Uf( :9 / ",  1the Internet: The role of Web site design”

1f(  " ;,  0#' 0  + 1( ( :) 4 e(
 / ! 

:)
* ,

 O& ( 1(  . "  1
 + " ", "(

1f' .fp
f "
" 0  4 
& + 1(K   0 

"f'* ,f   "f + 0 4 $  

K } $  + ",

. 1 " " #

“A Decade of Direct-to-Consumer
( Donohue,et al. (2007) ",

€ 0  "c(

( ", / !% Advertising of Prescription Drugs”

 ;( + %
K     0  1' ", 
K 

 
K 
   d  $& (
9

  ,,  4  %

.; T ",( 7, 3  " ( ,

" Self-Reported Influence of

( Khanfar, et al (2008) ",

Television-Based Direct-to-Consumer Advertising on Patient Seasonal

 1 Allergy and Asthma Medication Use: An Internet Survey"

* , 0
 L 1G   0(2 
K  4R 
9 ,  ",
35

 O& ( 1( 

&
  
 , * , ",     , "

1 
( %& : $(



)( (
&
 %12.4 :0

¥( " ( % !'


G %44 %(
  ,
K 
 "

,% ( + 1(K   ) ( ", 0 0 

 %80 ,
 :


 , G

 %(%39.1
 
 , %&
)( ( %( %6.7

.
K } %  
(


“A defense of direct-to-consumer
ff( Cox and D. Cox "ff,

7f 0f  "&f, T

" / !% prescription drug advertising”

,
& " 1 7'
># 0  "&, 0 ,"…  7, 

*R  , % #
 " * , *   ,"), 1  )
 ''*

Hf*  " O& ( 1(  .„

K   "(D' UK 7
&

f ,

G +/ )

 %  0  1(K  T  : L # 7'

1f(  €'f ;f# 9 ( €


 *  9 O& (
9

.+ 1(K 
   9 ( 0  + " ( 1
36

^ *,I

. L -  

 

   -!

   >-

   !

.5  *,'  ,    .  

,' %"

    )  4 ,
 37

 

"  0
&) ", "(  ,", :   ,", "%( '2  (

 *   1 : 0 1* , 0  ("(R ,) + e  ,("% "(

.1 % "&'# ;, #  4

 "(R ,D 14 7'

   -!

1, 1D ;
 ", €9 "  +( 1 / € 

: 0#  02' O%( ># * ,  , >#

 .c( ;(   ",

.1G  
 ")K
!  6&'#/ %#  ", 1G 
1(

   >-

– ) "% "( "  0

&
 "(
 ", : 


"2'
 0  "
 1' % 
(4 *  ) ,
 (484)

   !

1(R ,
 )   : K*
 "(  "(   *  :  #   6c(

 

& "% "( "  * "  1' T 

  " , "  1(R ,D

 (1A3 ) ,$ "2'



."#' 1(R ,D

38

"#' " , "  1(R ,D (1A3) 

', .!<0 5- .!<  .!<0

%  %  % 

%48.4 484 %50.7 507 %100 1000

"( 
     "(R ,D :  $( k(1A3) ) 
 %c

"(R , (21) %(

 k (%50.7) ",( . "(R , (507) %( : ,
  ",

",( 1( ,% 1 ")  e 1( ' * ,K "#' p

 " H&'*

 (2A3)   . (%48.4)"#' 1(R ,D

,"(

(%76.6)
 k 
  "( 
 (%53.2)
 (2A3))  39/

  "( 044

¦  $   %c§  . 50
   "( 


.
 
   %( %32
 (2A3) 
  .6 6
 

39

", "( " H&'* (2A3) 

  "& ",( "&2

257 53.2   8(

226 46.8 >(

141 29.2 "(, 29 A19

 

119 24.6 "(, 39 – 30



110 22.8 "(, 50 – 40



113 23.4 "(, 50 7

343 71.0 0 :0 d

140 29.0 0 p

157 32.5 U  "  D "#

326 67.5 ; 

.5  *,'  ,    .  

/ ,  . ", + K*

 H' *D 1 ;  1c(
 % 

:
,)
40

" #§ " 1D " &, 1 ;    ."(4 '..1

.", .c( 
( e +(

: 6''* ># )
  /  0  (2 7#) "(R ,D 0 ." '.2

8  0  $&,
 6   ", €9 7 0  1 1(

:
 + "(R ,D 1(  ."( 

 %( "} % &, ", !

(4 – 1) 12 K*
 ", "( "G H&'* 7   .1

A + &2 0  A ¨ " K*

 0#' 0  R 7 1G  .2

.
 +* 0 AA "( T  0  AUA "K 1K*  0  A;

." 1 ' 4R  7 1G  .3

.. L , 4R  7 1G  .4

0(4
 0 (Likert Scale) "1  8" 0,* O    D  )

(4) " 7 " "/ k1 (5) " 6 7 " "/
 ># ¨"(R ,D
 >4

7 p" " k " (2) "7 p" "/ k1 (3) "R#" "/ k1

(3A3)  0   "4K4 1 , / 0,* O  ˜,)i 4 k +# " " 6
41

  
 &
 5 (3A3) * -

3" } I

"(  2.33 – 1.00



",  3.66 – 2.34



" 5.00 – 3.67



:,' %"

" 0 ("  D  "&'# "#) spss "&'# "   D 

:"  "&'# &, * , 192  * # 

.("& ;,( , 1  ,0,# ,) 02'
'# ;, .1

192
"  , ,(, #(D   #(D) "#  ;, .2

K     , #(D 0,# ,  ,. !#(D * ,

 D    D   !, ,

& 1)  4R  "  

") y  ,(;,)  , G  :  G 

 ")K +)  69 "D

  0( % 62' .R,  ") 1(  (1A ,1+)
   
42

0( (1+)  D  ") 1( /  

K   ;,
 ")K

",( 82( :  G   (;,)  , G   / (    

/ . ,
G 
 0,     0( (1A)  D  ") 1( / 

. 3#' 8  :  G  T2*( / .d !, (;,)  , G  

.+ 14 82 ª( .2

:     )  4 ,

   )  4 , •

 # "   "(R ,D T ># )", + 0 7' 8) TG

f# / k(2 7#) "'  0 8  "&
9 

 H' *D 0


 D
 1*« "  "2 "G 1c#K
 " 

   )  . •

># 8 % #K'

  R  ", (Cornobach Alpha)  ;,# 

(3) f k "(,(  0 %60 .R,    2

 ( " 

:",  2 )


43

   5" I .5  (4e3) * -

I *5 . I  5

0.77 3  &2 0 

0.84 2
 +* 0 

0.91 3 "( T  0 

0.85 3 "K 1K*  0 

0.73 5 " 1 '

0.80 4 . L ,

0.83 6
 1)

0.82  +/ , 

(% 60 )
  
 "(R ,D 12 2  ) , 
 (4A3) 
 >#

0f "( +   "( 82(  %   / 

¦  0(  (%82)– /.

."4 O& (
44

>  *,I

\! I 
,' *'

 

     -

   .? &
45

  •

%  0  "2' "&'# ;, T * , O& ( T / '2  !%

f
  7,  4R # ", "( 
= # K*
 "(R ,D

1fG  0fG
,f&
#  O& ( T  ) .
& "& 1

:",

.", 0 "* , + 1  7  :

.", 19  * :0(4

.     - •

:
',
 e1

"f( "f  0
& )  R $#' $   4R L  A*

„"%

L , +2 " " 1#(D ",# 1, 

   >#
 ,

.(1A4)  39 0   0&'# # 

 0#' 0  § 12  
 46

12   L , " " 1#(D ",# 1,  (1A4)
0#' 0 

" L , !#(D
,  +2 )
+2   .

1 :2 
K  K*
 %(
 "
 $K :( e .5

0.80 4.02 

2 :2  0.80 4.02 "K :( e 

 
K   .6

3 :2  "
 4  %(
 "… "( T  e .14
0.98 3.99
%(
 p

4 :2  1.20 3.89

 0&p 0& *  1(K    .12

5 :2  0.80 3.73 $K :( 7) !' 

K    .7

6 :2  1.34 3.72 e "& 1K* 

  + 1(K } e   .11

7 ,  "( T 

 ) +' "( T  $ .13
1.22 3.59
%(
 p "…

8 ,  "
 4  %(
 "… $& 1K*  e .10
1.40 3.39
%(
 G

9 ,   + 1(K 


 +*
1 *R .9
1.37 3.36
 #

10 ,  1.11 2.34
 +*

1 + 1(K   .8
47

,  0.44 3.60  , 

1# /
& 1 ;,# 0#' 0  1 # / (1A4) 

%  0,# ,  : "( (4.2 A2.4)

   % ",# 1, 

%(
 "
 $K :( e ) H( 0  + 1
.(3.6)– 

("K :( e 

 
K  ) + (
K  K*


0,# ,  : "( (0.8). !#(R (4.2)0,# ,   "

 +*
1 + 1(K   + 1 #
# 0 .(3.6) 

,  : "( (1.11). !#( (2.34)0,# ,  +* " ,

: ",# 1,    L ,

    0#' 0    0,#

.:2  , 
 y 
 12

: .5  , e2

"( "  0
& )  " 1 ' 4R L  e*

„"%

L , +2 " " 1#(D ",# 1, 

   >#
 ,

 39 0   0&'# # 

 " 1 ' § 12  

.(2A4)

1 ,D ;   1 " 1#(D ",# 1,  4 (2A4)

"#' 1 ' 1  ", "( 

 48

!#(D
;   " ,  +2 )
.

1(K  0 " 1  .18

1 :2  0.78 4.36 "&

 4  y9 " 

" ,

1(K  0 $(

   .19

2 :2  0.73 4.17 1(K  0 $(


 4  " 

" , "&

K*
 " 1 "    .15
3 :2  1.23 3.86
€, 0&
 4  €
K 

1(K  K*
 " 1 74 .16
4 ,  1.36 3.04
" , "&
 4 " 

 " 1 0 ")  .17

5 ,  1.28 2.67 0&

K 
 4  "  1(K 

€,

0.51 3.62  , 

, 

/
& 1 ,/ 
( " 1 ' 1 # / (2A4) 

"f&
 4  y9 "  1(K  0 " 1  ) +2 1 #
49

.(0.78) .f !#(Rf (4.36) 0,f# f,   " ( " ,

f,  :f "( (2.67 – 4036)

   % ",# 1,  1# 


 ",# 1,    L ,
    .(3.62) –  0,#

.:2  , 

9  } e3

"( "  0 0& ) 

 * L , 4R e(  e*

„"%

(;f  )+2 " " 1#(D ",# 1, 

   >#
 ,

 0&'# #  O& (

 ". L ," § 12 (")   L ,

.(3A4)  39 0

1 ,D " ;  " 1#(D ",# 1,  4 (3A4)

. L , 1  ", "( 

!#(D
;   " ,  +2 )
.

1 :2  " 0 + 1(K     .20

0.71 4.29
; + ;(  UK

2 :2  
 ,

d, >#  23.
1.21 3.68

K } e 

3 ,  1.31 3.50 4R  D %(

 "… e* , .21
50

e . :9

4 ,  L # e . :9 L , .22

1.12 2.18

K  " e* ,

,  0.60 3.41 0,# , 


 
& 1/ ;,# . L ,  1 # / (3A4) 

+f ;f(  UKf " 0 + 1(K )     H( 0  +

"f( ,(0.71).f !#(Rf (4.29) 0,f# ,   " (;

L ,f "f H(f 0  + 1 #

# 0,(3.41)–  0,# , 

f,  +* " " 

K  " e* , L # e . :9

1f,  f  L ,f
   ,(1.12). !#(R (2.18) 0,#

.,  :2 
 ",#

" .  " A4

(;   ) +2 " " 1#(D ",# 1, 

   >#
 ,

39 0   0&'# # 

 " ,D § 12 (")   L ,

.(4A4) 

1 ,D ;   1 " 1#(D ",# 1,  4 (4A4)

 ) 1  ", "( 

!#(D
;   " ,  +2 )
.
51

1 :2  1 7' 0& e) 4R  28.

0.68 4.38

K  0 + 

2 :2  1 ") 0& e) 4R  26.

0.89 4.23

K  0 + 

3 :2  1 "R2  0& e) 4R  25.

0.85 4.22

K  + 

4 :2  1 y9 0& e) 4R  27.

0.85 4.22

K  0 + 

5 :2  0 02
 , 0& e) 4R  32.

0.85 4.22
7,D

6 :2  1 ' €( 0& e) 4R  29.

0.83 4.20
e "

7 :2  1 "4# 0& e) 4R  31.

1.05 3.98

K  0 + 

8 :2  1.14 3.88 e 0#' 0  0& e) 4R  .24

9 ,  ' ")' 0& e) 4R  30.

1.29 3.32
.
K } 1

:2  0.64 4.09  , 

",# 1,  K*

 ) 1 # 0/ (4A4)  

7' 0& e) 4R )  H( 0  + 1 # ." 1#(D

!#(R (4.38) 0,# ,   " (

K  0 +  1
52

0  + 1 #
# 0 (4.09)–  0,# ,  : "( (0.68).

" ,(.

K } 1 ' ")' 0& e) 4R )  H(

,(4.09)–  %  0,# ,  : "( (3.32)0,# ,  +*

.62  $c
  %   L ,
   

   .? & •

"f 2 1f92 ",f& ", "9  *  '2  0 ># 

1f9 T  ) L  *  '2  "% 1  ># ,%( " 2 

"f 1 e / "9   , #(D  * * , K*
 ",

f K*
 ( „
 1)  
K 4)  H( . d,

:0  e D  "&'#/ "D . 4

:   .?

0f
f )  0#' 0  "&'#/ "D .4  D : H01 •

α ) L , (
 
K  
P ( "% "( " 

:(0.05
 53

A4)  0 $& ( %c .   #(D #
/  "92 
"}

( 5

0
 )  0#' 0  44   #(D # O& (( 5A4) 

 
K  
P ( "% "( " 

! "D ! #    D

" (Sig) (F) (R2) (R)

3.84 0.00 14.76 0.11 0.33

f 0#' 0  4

  D  ")
R 39  ( 5A4) 


 (0.33) –
 
K  
P ( "% "( "  0
 )

0 f 4Rf/ f  0.01 "D L , 14.76 1G % (!) 0&'# ")

.
f 
K  
P ( "% "( "  0
 )  0#'

f
 ) 0
R 
 %11
 /   %11 – #  
 

( 6A4)  0 %c 0  (1) ) (β) ) U* ,D .0#' 0   /

"  0
 )  0#' 0  4R  (1) ) (β) ) ( 6A4) 

 
K  
P ( "% "(

Standardized Unstandardized

Sig. t Coefficients Coefficients Model

Beta Std. Error B

 54

0.00 14.18 0.23 3.33 14

0.15 A1.44 A0.06 0.04 A0.06 &2 1

0.05 1.97 0.09 0.03 0.06 +* 2

0.70 A0.39 A0.02 0.03 A0.01 1K*  3

Tffff D 4

0.00 6.50 0.30 0.04 0.23 "(

:" I ?I

f
P f(
 ) 
 +* 0  "&'#/ "D .4  D :H01A

(α 0.05) L , ( "% "( "  0

 
K 

 0 $& ( %c .   #(D #
/  "92 
"}

(7A4)

P (
 ) 
 +* 0  4   #(D # O& ((7A4) 

."% "( "  0

 
K  

Standardized Unstandardized

Sig. t Coefficients Coefficients Model

Beta Std. Error B

 55

0.00 14.18 0.23 3.33 14

0.05 1.97 0.09 0.03 0.06 +* 1

f) 
 +* 0  4 (1) 0&'# ")

R 39  (7A4) 


"f)
 1.97 – "% "( "  0
 
K  
P (


 +* 0  "&'#/ "D . 4  /   0.09
 (β) ) 

f( "f% "f( "  0

 
K  
P (
 ) 

(α 0.05) L ,

:! I ?I

Kf  
P (
 )  + &2 0  "&'#/ "D .4  D

(α 0.05) L , ( "% "( "  0

 

 0 $& ( %c .   #(D #
/  "92 
"}

(8A4)

 )  + &2 0  4   #(D # O& ( (8A4) 

"% "( "  0

 
K  
P (

Standardized Unstandardized

Sig. t Coefficients Coefficients Model

 56

Beta Std. Error B

0.00 14.18 0.23 3.33 14

0.15 A1.44 A0.06 0.04 A0.06 &2 1

f )  + &2 4 (1) 0&'# ")
R 39  (8A4) 


 ")
 A1.44 – "% "( "  0
 
K  
P (

+f f&2 0  "&'#/ "D .4  D /   0.04
 (β) )

f( "f% "f( "  0

 
K  
P (
 ) 

(α 0.05) L ,

: ?I


P (
 )  "& 1K*  0  "&'#/ "D .4  D

(α 0.05) L , ( "% "( "  0

 
K 

 0 $& ( %c .   #(D #
/  "92 
"}

(9A4)

 )  "& 1K*  0  4   #(D # O& ( (9A4) 

"% "( "  0

 
K  
P (
 57

Standardized Unstandardized

Sig. t Coefficients Coefficients Model

Beta Std. Error B

0.00 14.18 0.23 3.33 14

0.70 A0.39 A0.02 0.03 A0.01 1K*  1

f) f "f& 1K*  4 (1) 0&'# ")

R 39  (9A4) 


")
 0.39A – "% "( "  0
 
K  
P (


0 f "&'f#/ "fD .f4  D $( /   0.02A
 (β) ) 

"( "  0
 
K  
P (
 )  "& 1K* 

.(α 0.05) L , ( "%

5  I ?I

K  
P (
 )  "( T  0  "&'#/ "D .4  D

(α 0.05) L , ( "% "( "  0

 

 0 $& ( %c .   #(D #
/  "92 
"}

(10A4)
 58

)  "( T  0  4   #(D # O& ( (10A4) 

"% "( "  0

 
K  
P (


Standardized Unstandardized

Sig. t Coefficients Coefficients Model

Beta Std. Error B

0.00 14.18 0.23 3.33 14

T 

0.00 6.50 0.30 0.04 0.23 "(

f "( T  4 (1) 0&'# ")

R 39  (10A4) 


 6.50 – "% "( "  0
 
K  
P (
 )

0 f "&'f#/ "fD .4  $( /   0.30
 (β) )  ")

"( "  0
 
K  
P (
 )  "( T 

(α 0.05) L , ( "%

59

:!  ?I


P (
 )  " 1 ' "&'#/ "D .4  D

(α 0.05) L , ( "% "( "  0

 
K 

 0 $& ( %c .   #(D #
/  "92 
"}

(11A4)

P (
 )  " 1 ' 4 #(D # O& ( (11A4) 

"% "( "  0

 
K  

! "D ! #    D

" (Sig) (F) (R2) (R)

3.84 0.10 2.64 0.01 0.07

"f 1 '

  D  ")
R 39  (11A4) 


– "% "( "  0

 
K  
P (
 ) 

  0.10 "D L , 2.64 1G % (!) 0&'# ")
 (0.07)

f )  " 1 ' "&'#/ "D .4  D $( /

α ) L ,f ( "% "( "  0

 
K  
P (

(0.05
60

:  ?I

K  
P (
 ) 
 .') ;( "&'#/ "D .4  D

(α 0.05) L , ( "% "( "  0

 

 0 $& ( %c .   #(D #
/  "92 
"}

(12A4)


P (
 ) 
 . L , #(D # O& ( (12A4) 

"% "( "  0

 
K 

! "D ! #    D

" (Sig) (F) (R2) (R)

3.84 0.60 0.27 0.00 0.02

f) f
 . L ,  D  ")
R 39  (12A4) 


")
 (0.02) – "% "( "  0
 
K  
P (


"D .4  D $(R/   0.60 "D L , 0.60 1G % (!) 0&'#

0f
 
K  
P (
 ) 
 .') ;( "&'#/

.(α 0.05) L , ( "% "( " 

61

O& *,I

.,  \! !

 

\!

.,
62

  •

O& (  T ,  , $K*

 ., ", %  % +4 '2  §

f ,6' >#    ;,# 1'

 % ;    ># %/ ' 0 

.1'  O& ( 

 
 6(  '2 


\! •

 4R  " 1 19 69 1) 1Dd, 

 " +4/ ", 1

f "f "f, "  # 0 1%, O& ( + / 1' ,", 1G 

:O& (   / + ( ># R# .% 9 % Dd,

,  ,  4R $

 0#' 0  L , 4R  L ,
 #  O& ( 1( .1

. (2.34)– 0,#

,  4R $
 " 1 ' "%, 4R L ,
 #  O& ( 1( .2

. (3.62)– 0,# , 

0,# ,  ,  4R $

 . L , 4R L ,
 #  O& ( 1( .3

(3.41)–

 ) 4R 1  ", "(  " ,D 0&'# #  O& ( 1( .4

;,#  "  (4.09)– 0,# ,  4R $

 / :2  4R L , .

."* , 
63

0
 )  0#' 0   4 "&'#/ "D .4  %c .5

L , ( " 
 
K  
( "% "( " 

.(.05 ≥α)"D

(
 ) 
 +* 0#' 0   "&'#/ "D .4  .6

.(.05 ≥α)"D L , ( "% "( "  0

 A
K  

 )   &2 0#' 0   "&'#/ "D . 4   .7

(.05 ≥α)"D L , ( "% "( "  0

 
K  
(

 )  $& 1K*  0#' 0   "&'#/ "D .4  .8

(.05 ≥α)"D L , ( "% "( "  0

 
K  
(

 )  "( T  0#' 0   "&'#/ "D .4  .9

(.05 ≥α)"D L , ( "% "( "  0

 
K  
(

(
 )  " 1 '  "&'#/ "D .4  .10

.(.05 ≥α)"D L , ( "% "( "  0

 
K  


(
 )  . L ,  "&'#/ "D . 4   .11

.(.05 ≥α)"D L , ( "% "( "  0

 
K 
64

., •

.fc( f
f %/ '   0  ,", 
 "'* , O& ( K*


'   1( 0&'# #  :)

 % '#  0  O& ( e  ",

:"  1'  /

: ;,(  
 0 
K  c(  #
() 2 +9 .1

& "#' "& 1 

K 
 !%  % ; R  :   +9 .2

f f( !f 7f#  # 0     "
P % (

.
K 

1f) %   %,  "(  1
D

     .3

"f2  f 
Kf  f 0   8 (,  1  

.$ "  

f* f Rf D
6  % ) "( :9 1(K  L #  D .4

f 4d "9  "&* 1  

  R 
& "#'

.
& 1 , 1 

%2f  "f 1 f 0 7,  0&'* " 1  .5

># D  # $    D 
( $#,  y 
K 

.
  4d 1 , >#  £* % .
65

"f4#  "2'

 0  "
K 
K  &,   +9 .6

.' 9R $ !  $%    #

 0 
K 

+*
Reminder advertising ; 0# 1) 0 1    .7

Lf* €f( 0 T* 4 D 0#' 0  :    # +*

.
K }

(f :f ;f,(   "&92 "& 1(K } # :9 +9 .8

.K } "c(

. !f 
&f  
K 4R 8 " 1,  .9

.
 0 ' ># $( "'* 
K  H* 1 ,


K  7   1,
 
 ># 0'  .10

"f, K*

 0
(
 "#  R "4 $ '
&

.",  0 8  L* 

66

:: "&)

:!#0 >   ! 

• .Arab health website http://www.arabhealthonline.com/

• FDA website www.FDA.gov

• http://www.allergytherapeutics.com/reports%20and%20presentations%20su

b.aspx

• http://www.macmillandictionary.com/dictionary/british/awareness

• http://www.macmillandictionary.com/dictionary/british/awareness

• JFDA website www.jfda.jo

• America’s pharmaceutical industry announces guidelines on direct-

toconsumer advertising. PhRMA. Available

at:http://www.phrma.org/news_room/ press_releases.

• Jordan Pharmaceuticals and Healthcare Report,

2011http://www.researchandmarkets.com/reports/604182/jordan_pharmac

euticals_and_healthcare_report.pdfJPHR,2008

• The temporary Pharmacy Law of 2001.

67

:"( :

• Akanbi et al, 2011, The Association between Advertising and Sales

Volume,Journal of Emerging Trends in Economics and Management Sciences

117-123.

• Baylor, H., Norman A.D. (1998). Regulation of prescription drug promotion:

direct-to-consumer advertising, Clinical Therapeutics, 20(1), 86-95.

• BooneL. and Kurtz D., (2012). Contemporary Marketing, south-western

Cengage Learning, 13th edition, page 500.

• Borden N, The Concept of the Marketing Mix, Journal of Advertising

Research ,June): 2–7.

• Brekke, K.R. & Kuhn M. (2005). Direct to consumer advertising in

pharmaceutical markets, Journal of Health Economics, 25 (2006), 102–130.

• Burande D, (2008). Drug Store And Business Management, Nirali Prakashan,

10th Edition.

• Costae D, (2009).Essays on the Economics of Drug Pricing and Advertising,

Eisenhower Parkway.

• Cox, A.D. & Cox, D. (2010). A defense of direct-to-consumer prescription

drug advertising, Business Horizons, 53(2), 221-228.

• Direct-to-consumer promotion; public hearing. Fed Regist. 1995;60.

• Donohue, J.M., Cevasco, M., & Rosenthal, M.B. (2007). A Decade of Direct-

to-Consumer Advertising of Prescription Drugs, the New England journal

of medicine, 357(7), 673-681.

68

• Dukes, D.E., Rogers, J.F., Paine, E.A. (2001). What You Should Know about

Direct-to-Consumer Advertising of Prescription Drugs, 68 Def. Counsel J.,

36 (2001).

• Elliott, C. &Chambers, T. (2004). Prozac as a way of life Studies in social

medicine, UNC Press Books.

• Firestone, O.J. (1967).The economic implications of advertising, Methuen.

• Gellad F. et al 2007, Direct-to-Consumer Advertising of PharmaceuticalsThe

American Journal of Medicine W. Lyles 120, 475-480.

• George S, The Capabilities of Market-Driven Organizations, Journal of

Marketing, 58, no. 4 (October 1994): 37–52.

• Hansen R.A., Marcus Droege (2005). Methodological challenges

surrounding direct-to-consumer advertising research—the measurement

conundrum, Research in Social and Administrative Pharmacy, 1(2), 331-

347.

• Hansen,R.A., Schommer, J.C., Cline, R.R.,Hadsall, R.S.,Schondelmeyer,

S.W., & Nyman, J.A. (2005). The association of consumer cost-sharing and

direct-to-consumer advertising with prescription drug use,Research in

Social and Administrative Pharmacy, 1(2), 139-157.

• Harvey R and Champe P, (2011), Lippincott Illustrated Reviews:

Pharmacology, lipincott Williams and wilkines.

• Hickmann, M.A. (2003). The Food and Drug Administration (FDA),Nova

Publishers.

• Hollon M.(2005)Direct-to-consumer advertising: a haphazard approach to

health promotion. JAMA; 293.

69

• IIZUKA T, (2005).The Effect of Prescription Drug Advertising on Doctor

Visits,Journal of Economics & Management Strategy, Volume 14, Number 3,

Fall 2005, 701–727.

• Jacoby J. and Chestnut R. (1978), Brand loyalty: measurement and

management, New York: Wiley.

• Jhon R, et al, (2011).Organizational Behavior, John Wiley & Sons, 12 edition,

686.

• Kessler D, Pines W. (1990)The federal regulation of prescription drug

advertising and promotion. JAMA.264.

• Kessler D, Pines W. (1990). The federal regulation of prescription drug

advertising and promotion. 264(18):2409-2415.

• Klieman, M.A.R. (2011). Encyclopedia of Drug Policy, SAGE.

• Lamb C, Joseph F, (2011), Essentials of Marketing, south-western Cengage

Learning, 7th edition, page 619.

• Larry Steven Londre Marketing, IMC, Advertising, Promotion, Media

and More. 2009

• Lucinda L. Maine,1998, Direct-to-Consumer Advertising:A Pharmacy

Perspective, CLINICAL THERAPEUTICS VOL. 20

• Lyles A. Direct marketing of pharmaceuticals to consumers.(2002) Annual

Review Public Health. 73-91.

• Maine, L.L. (1998). Direct-to-consumer advertising: a pharmacy

perspectiveClinical Therapeutics, 20(1), 104-110.

• McCarthy E, Basic Marketing: A Managerial Approach, 13th ed.

(Homewood, ILIrwin, 1999).

70

• Norris, P., Nelson, L., Ling, K.L., Skellett, L., Hoo, J., Va’ai, C., Gates, A.

(2004) Advertising of medicines on New Zealand television, Journal of the

New Zealand Medical Association, 118(1215).

• Perri, M., Shinde, S., & Banavali, R. (1999). The past, present, and future of

direct-to-consumer prescription drug advertising, Clinical Therapeutics,

21(10), 1798-1811.

• Pharmaceutical Manufacturing Sector Study, LITERATURE REVIEW OF

THE SOUTH AFRICAN PHARMACEUTICAL INDUSTRY, 2000

• Richardson Lee and Luchsinger Vince, 2005, Direct-To-Customer Advertising

of Pharmaceutical Products: Issue Analysis and Direct-To-Consumer

Promotion, The Journal of AmericanAcademy of Business, Cambridge , Vol. 7

, Num. 2.

• Ronald J. et al, 2003 A 3-stage model foe Assessing the Probable Economic

Effects of Direct-to-Consumer Advertising of Pharmaceuticals ,university of

Arizona, Tucson, Arezona.

• Saxena S, (2006). A review of marketing Strategies work by deferent

pharmaceutical companies, Rakshpal Bahadur Management Institute Bareilly-

243001, India.

• Saxena, s (2006) A REVIEW OF MARKETING STRATEGIES WORK BY

DIFFERENT PHARMACEUTICAL COMPANIES Rakshpal Bahadur

Management Institute.

• Shah, M.B., Bentley, J.P., McCaffrey, D.J., &Kolassa, M. (2005). Direct-to-

consumer advertising and the patient-physician relationship, Research in

Social and Administrative Pharmacy,1(2), 211-230.

• Syndigate, a 2008 , Jordan Press & publishing Co

71

• Tsakonas, G. &Papatheodorou, C. (2006). Analysing and evaluating

usefulness and usability in electronic information services, Journal of

Information Science, 32(5), 400-419.

• Vogel, R.J., Ramachandran, S., & Zachry, W.M. (2002). A 3-stage model for

assessing the probable economic effects of direct-to-consumer advertising

of pharmaceuticals, Clinical Therapeutics, 25(1), 309-329.

• Wankel, C. (2009) Encyclopedia of business in today's world, volume 1,

SAGE.

• Wilkes S, Bell RA, Kravitz RL.(2000)Direct-to-consumer prescription drug

advertising: trends, impact, and implications. Health Aff. 110-129.

• Woloshin S, Schwartz LM, 2001. Direct-to-consumer advertisements for

prescription drugs: what are Americans being sold? Lancet. 2001; 1141–

1146.

• Zachry, W.M. & Ginsburg D.B. (2001). Patient autonomy and the regulation

of direct-to-consumer advertising, Clinical Therapeutics, 23(12), 2024-2037

• Shaw A. (2008), Direct-to-Consumer Advertising (DTC) of Pharmaceuticals,

Discovery Guides, p: 5.
72

:7#K "&)

:(!<0 )   1 :0/ 

' ' = 

, 7 "

 D "

"(    ,)

"(R ,

: "  1* /   ª

", : $& % ) 

& 
K 4 )
( ",
 ># 
 , "  '# 1   ,D ( "% "( " 
&  "
., 7 " 0   +/ 0

", "… + 1(K  + 

& 1) #
D €K , !% e 
T 0( 7, 1%  :2( ",  
 ># :)  "#  &,

& + "
73

:  +&2  0  " 9 ") "(R ,D "&  92  

Tp $ ",  , % '#R, 0  1

R  
 d

.  0 >

 '0 4 * ?I 

># !/

;*  0 : 0(D' * +#  

74

( +# "  *) ",(  0  "D ( √ + :9 : ,& .!

:8( A1

4( □   □
: A2

50
 4  □ "(, 50A41 □ "(, 40A31 □ "(, 30A21 □
"(,

:0 d A3

0 p □0□

: "   "# A4

U  □ ;  □
75

.
! L-

K*
 0( 7, 0 "… 
K 4R
  7 

. e,( . : 0 ( √ ) + :9
 , 

 

Healthcare awareness : D

7 D 7 D R# 7 7 12

 

"
 $K :( e .5

K  K*
 %(



e 
 
K   .6
"K :(

7) !' 

K    .7
$K :(

1 + 1(K   .8

 +*

 +*
1 *R .9
#  + 1(K 


"… $& 1K*  e .10
G "
 4  %(

%(


  + 1(K } e   .11
e "& 1K* 
76

0& *  1(K    .12


 0&p
) +' "( T D $ .13
G .K "( T D

%(

"… "( T D e .14
G "
 4  %(

%(


source of healthcare information : (4

7 p p R# 7 7 12

 7 

 " 1 "    .15
4  €, 0&
K  K*
€
K 


K*
 " 1 74 .16

 4  "  1(K 
" , "&

" 1 0 ")  .17

 4  "  1(K 

€, 0&
K 

0 " 1  .18

" , "& 1(K 
1(K 
 4  y9
" 

0 $(

   .19
4  " , "& 1(K 
77

1(K  0 $(


" 

income level : 44

p p R# 7 7 12 )

 7 

7


" 0 + 1(K     .20

; + ;(  UK
4R  D %(
 "… e* , .21
e . :9
L # e . :9 L , .22

K  " e* ,

 ,
d, >#  23.

K } e 

0#' 0  0& e) 4R  .24

e
:^ L-
1 "R2  0& e) 4R  25.

K  + 
.
 e)  
K1
 4R ")L
0&"&, 
e) 4R  7 26.

K  0 + 

. ec( "%
 ;,( 1
: 0 ( √0&
y9 ) +/ :9
e) 4R 

27.

K  0 + 
1 7' 0& e) 4R  28.

K  0 + 
customer DecisionAmaking : 
' €( 0& e) 4R  29.
7 p p R# 7 7 12
e " 1
 7  ' ")' 0& e) 4R  30.
.
K } 1
78

1 "4# 0& e) 4R  31.


K  0 + 
02
 , 0& e) 4R  32.
7,D 0

L* 1c#K .
:
……………………………………………………………………………………………………
……………………………………………………………………………………………………
…………………………………………………………………………………………………….

!0
#' L 
79

5- +,& 0 

"'*
, " "' !( # . 1

"( " "'  0( # . 2

"'*
, " "' 0(%  # . 3

"'*
, " "' +  +p . 4

A "' ;#  . 4